Comparative Pharmacokinetics and Bioequivalence Evaluation of Two Formulations of Pramipexole Dihydrochloride Extended-Release Tablets in Healthy Chinese Subjects Under Fasted and Fed States: A Randomized, Open-Label, Single-Dose, Two-Period...

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2023 Aug 21

PMID 37600497

Authors

Ling Yang

Liangliang Zhang

Zhu Luo

Affiliations

Soon will be listed here.

Abstract

Background: Pramipexole dihydrochloride extended-release tablet is a novel long-acting form of non-ergot dopamine agonist indicated as one of main therapeutic approaches for Parkinson's disease. However, pharmacokinetic properties of extended-release pramipexole in healthy Chinese subjects remain unclear.

Methods: A single-center, randomized, open-label, two-period crossover, single-dose study was performed to investigate comparative pharmacokinetics and evaluate bioequivalence of 0.375 mg test (Yangtze River Pharmaceutical Group Co., Ltd.) and reference (Trade name: Sifrol, Boehringer Ingelheim Pharma GmbH & Co. KG) formulations of pramipexole dihydrochloride extended-release tablets in healthy Chinese subjects under fasted and fed states.

Results: A total of 56 subjects (28 in each dietary trial) were enrolled and randomized. After single dose of 0.375 mg test and reference formulations under fasted condition, main pharmacokinetics of pramipexole were as follows: peak concentration (C) were 409.33±95.93 and 413.77±132.03 pg/mL; plasma area under concentration-time curve from time 0 to last measurable concentration (AUC) were 8801.95±1966.83 and 8646.37±2600.49 h*pg/mL; AUC from time 0 to infinity (AUC) were 9469.03±1991.61 and 9082.95±2666.26 h*pg/mL; elimination half-life (t) were 11.98±3.91 and 9.85±2.63 h; both time to reach C (T) were about 4.50 h, respectively, for test and reference formulations. The 90% confidence intervals of geometric mean ratios (test/reference) of C, AUC and AUC under fasted and fed conditions were all within 80-125%. Following administration under fed condition, C and T for both test and reference formulations slightly increased and prolonged to 5.0 h, respectively, but AUC approximately remained unchanged compared with dosing under fasted condition. Test and reference formulations showed similar bioequivalence and favorable safety under fasted and fed states.

Conclusion: Test and reference formulations of pramipexole dihydrochloride extended-release tablets (0.375 mg) showed similar bioequivalence and well safety and tolerability in healthy Chinese subjects under fasted and fed states, which supports further investigations of test formulation in patients with Parkinson's disease.

References

Salawu F . Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole. Patient Prefer Adherence. 2012; 6:49-54. PMC: 3269317. DOI: 10.2147/PPA.S11841. View

Jenner P, Konen-Bergmann M, Schepers C, Haertter S . Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther. 2010; 31(11):2698-711. DOI: 10.1016/j.clinthera.2009.10.018. View

Tayarani-Binazir K, Jackson M, Rose S, Olanow C, Jenner P . Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Mov Disord. 2010; 25(3):377-84. DOI: 10.1002/mds.22960. View

Stocchi F, Torti M, Fossati C . Advances in dopamine receptor agonists for the treatment of Parkinson's disease. Expert Opin Pharmacother. 2016; 17(14):1889-902. DOI: 10.1080/14656566.2016.1219337. View

Shen T, Ye R, Zhang B . Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials. Eur J Neurol. 2017; 24(6):835-843. DOI: 10.1111/ene.13303. View

Chen X, Zhang Q, Wen S, Chen F, Zhou C . Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta-analysis. Eur J Neurol. 2022; 30(3):762-773. PMC: 10099912. DOI: 10.1111/ene.15635. View

Hauser R, Schapira A, Rascol O, Barone P, Mizuno Y, Salin L . Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord. 2010; 25(15):2542-9. DOI: 10.1002/mds.23317. View

Perez Lloret S, Rascol O . Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease. Expert Opin Pharmacother. 2010; 11(13):2221-30. DOI: 10.1517/14656566.2010.510515. View

Hametner E, Seppi K, Poewe W . Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. Clin Interv Aging. 2012; 7:83-8. PMC: 3324991. DOI: 10.2147/CIA.S11829. View

10.

Antonini A, Calandrella D . Pharmacokinetic evaluation of pramipexole. Expert Opin Drug Metab Toxicol. 2011; 7(10):1307-14. DOI: 10.1517/17425255.2011.614232. View

11.

Wang Y, Sun S, Zhu S, Liu C, Liu Y, Di Q . The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study. Transl Neurodegener. 2014; 3:11. PMC: 4128609. DOI: 10.1186/2047-9158-3-11. View

12.

Schapira A, Barone P, Hauser R, Mizuno Y, Rascol O, Busse M . Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011; 77(8):767-74. DOI: 10.1212/WNL.0b013e31822affdb. View

13.

Obeso J, Stamelou M, Goetz C, Poewe W, Lang A, Weintraub D . Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017; 32(9):1264-1310. PMC: 5685546. DOI: 10.1002/mds.27115. View

14.

Frampton J . Pramipexole extended-release: a review of its use in patients with Parkinson's disease. Drugs. 2014; 74(18):2175-90. DOI: 10.1007/s40265-014-0322-5. View

15.

Hauser R, Schapira A, Barone P, Mizuno Y, Rascol O, Busse M . Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. Eur J Neurol. 2014; 21(5):736-43. PMC: 4282380. DOI: 10.1111/ene.12375. View

16.

Schapira A, Barone P, Hauser R, Mizuno Y, Rascol O, Busse M . Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol. 2012; 20(1):50-6. DOI: 10.1111/j.1468-1331.2012.03712.x. View

17.

Poewe W, Rascol O, Barone P, Hauser R, Mizuno Y, Haaksma M . Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011; 77(8):759-66. DOI: 10.1212/WNL.0b013e31822affb0. View

18.

. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA. 2000; 284(15):1931-8. DOI: 10.1001/jama.284.15.1931. View

19.

Shen Z, Kong D . Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease. Medicine (Baltimore). 2018; 97(34):e11316. PMC: 6112990. DOI: 10.1097/MD.0000000000011316. View

20.

Fox S, Katzenschlager R, Lim S, Barton B, de Bie R, Seppi K . International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018; 33(8):1248-1266. DOI: 10.1002/mds.27372. View